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Abstract
Activation of both CD4
+ and CD8
+ T cells is required for an effective immune response to an M. tuberculosis infection.
However, infected macrophages are poor antigen presenting cells and may be spatially separated from recruited T cells,
thus limiting antigen presentation within a granuloma. Our previous studies showed that infected macrophages release
from cells small membrane-bound vesicles called exosomes which contain mycobacterial lipid components and showed
that these exosomes could stimulate a pro-inflammatory response in naı ¨ve macrophages. In the present study we
demonstrate that exosomes stimulate both CD4
+ and CD8
+ splenic T cells isolated from mycobacteria-sensitized mice.
Although the exosomes contain MHC I and II as well as costimulatory molecules, maximum stimulation of T cells required
prior incubation of exosomes with antigen presenting cells. Exosomes isolated from M. bovis and M. tuberculosis infected
macrophages also stimulated activation and maturation of mouse bone marrow-derived dendritic cells. Interestingly,
intranasal administration of mice with exosomes isolated from M. bovis BCG infected macrophages induce the generation of
memory CD4
+ and CD8
+ T cells. The isolated T cells also produced IFN-c upon restimulation with BCG antigens. The release
of exosomes from infected macrophages may overcome some of the defects in antigen presentation associated with
mycobacterial infections and we suggest that exosomes may be a promising M. tuberculosis vaccine candidate.
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Introduction
Granulomas are required for controlling an M. tuberculosis (Mtb)
infection and the site of a chronic inflammatory response.
Granuloma formation requires CD4
+ T cells as mice deficient in
these cells fail to form granulomas or control the infection [1].
Initial activation of CD4
+ T cells occurs within the draining lymph
node and involves class II MHC antigen presentation by M.
tuberculosis-infected dendritic cells (DCs) as well as exposure to DC-
derived IL-12p70 [2] [3]. Activated CD4+ T cells migrate to the
site of infection and produce cytokines and chemokines, especially
IFN-c, which serves to recruit and activate macrophages
promoting granuloma formation and the inflammatory process
[4]. Maintaining the granuloma and controlling the infection
requires continued antigen presentation mediated by antigen
presenting cells (APCs) within the granuloma. CD8
+ T cells are
also required for maintaining an effective immune response at
later stages of infection [5] [4]. This requires processing of
mycobacterial antigens and presentation onto class I MHC by cells
within the granuloma.
Mtb has multiple mechanisms to inhibit antigen processing and
presentation within an infected macrophage [6]. Quantitative
analysis by Gercken et al. indicates that monocytes cocultured with
Mtb for 6 days showed a 3- to 10-fold decrease in their ability to
stimulate Th1 cell proliferation when compared with uninfected
controls [7]. However, granulomas from Mtb infected humans and
mice maintain significant CD4
+ T cell activation and IFN-c
production [8] [9]. Moreover, there is significant activation of
CD8
+ T cells within the granuloma [10] despite the sequestration
of the Mtb within a phagosome and away from the class I antigen
processing pathway. Analysis of the cellular architecture within a
human granuloma also indicates a spatial separation between the
Mtb and the CD8
+ T cells [11].
Despite the data indicating that infected macrophages are
relatively poor presenters of Mtb antigens to both CD8
+ and
CD4
+ T cells, there is a robust acquired immune response
associated with an Mtb infection which implies that alternative
mechanisms of antigen presentation may be functioning within a
granuloma. In this report we identify a previously unknown
mechanism for antigen cross-priming in the context of a
mycobacterial infection. Previous studies have shown that DCs,
macrophages and other cell types release small 30 to 100 nm
vesicles. This exocytic process involves fusion of multivesicular
bodies (MVBs) with the plasma membrane and subsequent release
of the intraluminal vesicles as exosomes [12]. The membranes of
the MVBs have their origin within the endocytic network and thus
exosomes consist of proteins and lipids present within this network.
Exosomes released from mycobacterial-infected macrophages
contain bacterial components and stimulate a MyD88-dependent
proinflammatory response in naı ¨ve macrophages [13]. The
isolated exosomes also contain both class I and II MHC as well
as costimulatory molecules. Interestingly, prior studies have
PLoS ONE | www.plosone.org 1 June 2008 | Volume 3 | Issue 6 | e2461indicated that exosomes containing tumor antigens are potent
stimulators of tumor-specific T cells in vitro and in vivo [14].
Therefore in this study we tested the hypothesis that exosomes
released from M. bovis BCG infected macrophages contain
mycobacterial antigens which could stimulate a T cell response.
We found that exosomes released from BCG infected macro-
phages upon intranasal administration of C57Bl/6 mice induced a
CD4
+ and CD8
+ memory T cell response. We also found that
exosomes released from BCG infected macrophages could
stimulate DC activation and maturation in vitro. Together the
data demonstrates a potential mechanism for antigen cross-
priming during a mycobacterial infection and suggest that isolated
exosomes, which have both antigenic and adjuvant characteristics,
may be an alternative tuberculosis vaccine candidate.
Results
Presence of the Ag85 complex on exosomes from M.
bovis BCG-infected J774 cells
Studies by David Russell and colleagues demonstrated that
macrophages infected with M. bovis BCG release vesicles
containing mycobacterial lipids [15] [16]. In previous studies we
also observed that vesicles released from macrophages infected
with M. avium, BCG or M. tuberculosis contain LAM, glycopepti-
dolipids, and the19 kDa lipoprotein. Flow cytometric analysis of
these vesicles indicated that they contained exosome-associated
proteins including CD86, CD80, LAMP1, LAMP2 and MHC
class I and II [13]. Importantly, the vesicles were negative for
FCR-cII/III and annexin-V staining which are known markers of
apoptotic vesicles [13].
Both mycobacterial lipid and protein components have been
shown to be antigenic [17]. We previously reported that exosomes
released from infected macrophages contain mycobacterial glyco-
lipids; however, protein composition was not evaluated in these
studies [13]. Therefore we purified exosomes released from BCG-
infected macrophages as described previously [13] and probed the
exosomes using antibodies against HBHA, a-crystallin, PstS1 and
antigen 85 complex (Ag85). Although exosomes from BCG infected
macrophages did not have detectable levels for HBHA, a-crystallin
or PstS1, we did observe a strong band of the correct size for Ag85
in our Western blot (data not shown). Using a polyclonal antibody
made against Mtb whole cell lysate (minus LAM), we observed ,10
protein bands on Western blot specific to exosomes isolated from
BCG infected macrophages (data not shown).
Activation of T cells by exosomes from BCG-infected
macrophages
Exosomes from infected J774 cells contain mycobacterial
antigens as well as class I and II MHC and CD86 suggesting
that these vesicles may be capable of inducing an antigen-specific
T cell response. This possibility is further strengthened by previous
studies showing that exosomes containing tumor antigens can
stimulate antigen-specific T cell responses [18] [19]. Therefore we
incubated exosomes from BCG infected or uninfected J774 cells
with total splenocytes isolated from BCG infected mice. As shown
in figure 1A, exosomes from infected cells induced intracellular
IFN-c expression in both CD8
+ and CD4
+ T cells while exosomes
from uninfected cells failed to induce IFN-c. We found 28% and
17.5% of the total CD4
+ and CD8
+ T cells respectively, produced
IFN-c upon exosome treatment suggesting that exosomes have a
significant antigenic component for both T cell populations. T cell
activation by exosome treatments was further evaluated by
measuring cell proliferation and CD69 expression. Cells were
labeled with the fluorescent dye CFSE prior to exosome treatment
Figure 1. Activation of BCG sensitized splenic T cells by
exosomes from BCG-infected macrophages. Balb/C mice were
infected with BCG (1610
6/mouse). Four weeks post-infection, spleno-
cytes were harvested. (A) Splenocytes from BCG infected mice were
cultured with BCG or UI exosomes, BCG lysate or media. 12 hr post-
treatment, cells were stained with anti-CD4-PE, anti-CD8-PE-Cy5 and
anti-IFN-c-FITC and analyzed by flow cytometry. (B) Splenocytes from
BCG infected mice, labeled with 2.5 mM CFSE, were treated with BCG or
UI exosome, BCG lysate or media. 72 hr post-treatment, cells were
stained with anti-CD4-PE or anti-CD8-PE-Cy5 and analyzed by flow
cytometry. (C) Splenocytes from BCG infected mice were cultured with
BCG or UI exosomes, BCG lysate or media. 72 hr post-treatment, cells
were stained with anti-CD4-PE, anti-CD8-FITC and anti-CD69-PE-Cy5
and analyzed by flow cytometry. Total lymphocytes were gated using
FSC/SSC. CFSE, CD69 and intracellular IFN-c levels were detected on
gated CD4
+ and CD8
+ lymphocytes. Results are shown as percent
positive. Cells were negative for staining with isotype control
antibodies. Results are representative of at least 3 independent
experiments.
doi:10.1371/journal.pone.0002461.g001
T Cell Activation by Exosomes
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proliferate, the CFSE staining diminishes. Splenic cells obtained
from BCG-infected mice were treated with exosomes and as
shown in figure 1B, CD4
+ and CD8
+ T cells showed diminished
CFSE staining upon treatment with exosomes from infected but
not from uninfected J774 cells. CD69 expression, which is a
marker of T cell activation [20], was also elevated in T cells treated
with exosomes from BCG infected J774 cells (Fig. 1C).
Exosome-mediated activation of T cells requires
presentation by APCs
Exosomes bearing tumor antigens have been shown to induce a
tumor-specific T cell response. However, it is less clear whether
exosomes can induce T cell activation directly or require uptake
and subsequent presentation of exosome-derived antigens by
APCs; although the most recent data supports the latter [21]. To
address this question in the context of exosomes from BCG
infected cells, CD3+ T cells were isolated from the spleens of BCG
infected mice and treated with exosomes in the presence or
absence of mouse bone marrow-derived DCs. As shown in figure 2,
intracellular IFN-c as well as CD69 expression were increased
modestly in both CD4
+ and CD8
+ T cells when the cells were
treated with exosomes alone compared to cells treated with media
alone. However, levels of IFN-c and CD69 expression by T cells
were considerably elevated when DCs were present during the
incubation, suggesting that uptake and presentation by APCs is
required for optimal stimulation.
Activation of T cells in vivo by exosomes from BCG-
infected macrophages
To determine if exosomes could activate naı ¨ve T cells in vivo,
C57Bl/6 mice were treated intranasally with exosomes +/2 the
adjuvant CpG. Two weeks after the final dose, mice were
sacrificed and their spleens, lungs and mediastinal lymph nodes
(MLN) were isolated. Single cell suspensions from the various
organs were stimulated ex vivo with BCG lysate. As shown in
Figures 3A and 3B, there was a small but significant population of
CD4
+ T cells from all three organs which produced IFN-c upon
restimulation with BCG antigens. As expected, this was specific to
mice treated with exosomes from BCG-infected macrophages as
exosomes from uninfected cells failed to stimulate IFN-c
production. The activation of T cells was not limited to CD4
+
cells as exosomes were also able to stimulate a CD8
+ T cell
response as defined by IFN-c production upon restimulation with
BCG antigens (Fig. 3C and D). Interestingly, the addition of the
adjuvant CpG only marginally increased the effectiveness of the
exosomes. This contrasts with what is observed for subunit
vaccines using mycobacterial proteins, as the activation of a T cell
response requires the addition of an adjuvant [22]. As a control we
also isolated T cells from intranasally BCG infected mice and
stimulated the T cells in vitro with BCG antigens. As anticipated,
there was a more robust IFN-c response as 5.8%, 14% and 12% of
the CD4
+ T cells in the spleen, lung and MLN respectively were
positive for cytokine production.
An effective tuberculosis vaccine requires the development of
memory CD4
+ and CD8
+ T cells. Therefore, to determine if
exosomes could induce a memory response, mice were intranasally
treated with the different exosome preparations +/2 CpG
adjuvant and organs were harvested as described above. As shown
in figures 4A and B, exosomes from BCG-infected but not from
uninfected macrophages induced a population of effector memory
T cells (CD62L-low, CD44-high) in the spleen, lung and MLN. A
similar result was obtained for CD8
+ T cells (Fig. 4C and D). As
observed for IFN-c production, the presence of CpG plus
exosomes resulted in only a marginal increase in the number of
CD62L
low, CD44
high effector memory T cells compared to
exosomes alone. In contrast, mice vaccinated intranasally with
BCG produced significantly higher numbers of effector memory
CD4
+ T cells with percent positive being 11%, 7.1% and 21.2% in
the spleen, lung and MLN respectively.
Exosomes from Mtb- and BCG-infected macrophages
stimulate DC maturation and activation
Since exosomes were shown to stimulate a T cell response in the
absence of adjuvant, we tested their ability to activate mouse bone
marrow-derived DC. Intracellular IL-12p40 was measured as this
cytokine is required for stimulating a TH1 response and is a classic
marker of DC activation. As expected, non-activated DCs were
positive for CD11c and negative for intracellular IL-12p40
(Fig. 5A). The same profile was seen for DCs treated with
exosomes isolated from uninfected J774 cells. In contrast, ,50 to
60% of the DCs treated with exosomes from Mtb or BCG-infected
cells were positive for intracellular IL-12p40 staining (Fig. 5A). To
address DC maturation, the cells were analyzed for CD83, CD86
and MHC class II expression. As shown in figure 5B, treatment of
DCs with exosomes isolated from infected but not from uninfected
cells resulted in a marked increase in expression for all three
markers. We did not observe any clear differences between
exosomes isolated from Mtb- or BCG-infected macrophages in
their ability to activate DCs or induce DC maturation. This
suggests that potential differences between exosomes derived from
Mtb- and BCG-infected macrophages do not affect their ability to
stimulate DC maturation and activation.
Discussion
M. tuberculosis as well as other mycobacterial species shed or
release both lipid and protein components during growth in broth
culture and in macrophages [23] [24]. Some of the shed
mycobacterial components including the Ag85 complex and
ESAT6 are known to be immunogenic and have been used
effectively as subunit vaccines [25]. However, the accessibility of
these proteins to the immune system during an in vivo infection is
less clear. A number of studies have indicated that infected DCs
and macrophages are poor presenters of mycobacterial antigens
[26]. Nevertheless, a robust T cell response to shed mycobacterial
components is observed during an in vivo Mtb infection in mice
[27] as well as in tuberculosis patients [9]. This suggests that
alternative mechanisms for presenting mycobacterial antigens may
be functioning in vivo. One previously described mechanism for
cross-presentation of Mtb antigens in the context of CD8
+ T cells
is through release of apoptotic blebs. Work by Schaible et al.
demonstrated that apoptotic vesicles obtained from Mtb infected
macrophages contain mycobacterial antigens and can stimulate
MHC class I and CD1b restricted T cells. Engulfment of the
apoptotic vesicles by DC was required for cross-presentation to T-
cells isolated from a mycobacteria-sensitized donor [28]. Never-
theless, macrophages infected with pathogenic strains of Mtb show
minimal apoptosis, thus limiting this potential mechanism for
activating antigen-specific CD8
+ T cells [29] [30]. Surprisingly,
recent data suggest that Mtb can escape from the phagosome into
the cytoplasm within infected macrophages and DCs and
therefore the released mycobacterial antigens may be exposed to
the class I antigen presentation pathway [31]. Here we describe an
alternative mechanism for presentation of mycobacterial antigens
through exosomes released from infected cells and we hypothesize
that this mechanism of cross-presentation could function in vivo to
T Cell Activation by Exosomes
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+ T
cells were purified from the spleens of BCG infected mice. Purified CD3
+ T cells (5610
5) were cultured alone or in presence of BMDCs (1610
5) with or
without BCG exosomes. Cells were cultured for 12 hr and stained with anti-CD4-PE, anti-CD8-PE-Cy5 and anti-IFN-c-FITC (A) or cultured for 72 hr and
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exosomes activate CD8
+ T cells, indicating that antigens present
on exosomes can be processed through the class I MHC
presentation pathway. We predict that these exosomes may be
responsible, at least in part, for the robust CD8
+ T cell response
seen during the course of an Mtb infection.
Prior studies have shown that exosomes can function to
modulate immune responses, including immune stimulation and
immune suppression [12]. Tumor-derived exosomes, which are
enriched in tumor antigens, are a novel source of antigens for
promoting CTL cross-priming. Immature DCs secrete exosomes
and can transfer functional MHC-peptide complexes to activated
DCs. Consistent with a stimulatory role in the immune response,
exosomes secreted by DCs which carry tumor antigens can elicit T
cell activation in vivo [32] [33]. Recent studies have also shown that
exosomes containing microbial antigens can protect against
infection. Studies by Colino and Snapper showed that injecting
mice with exosomes containing Streptococcus pneumoniae’s capsular
polysaccharide type 14 cross-reactive antigen induced a protective
antibody response [34]. Mice treated with exosomes derived from
Figure 3. Exosomes from BCG infected macrophages induce antigen-specific IFN-c producing T cells. Lymphocytes from lungs, MLN
and spleens were isolated from mice intranasally injected with exosomes or PBS and cultured in the presence or absence of BCG lysate. Cells were
stained with anti-CD4-PE, anti-CD8-PE and anti-IFN-c-FITC and analyzed by flow cytometry. (A) T cells stained for CD4 and intracellular IFN-c. (B)
percentage of total CD4
+ T cells which expressed IFN-c. Values are mean6SD of two independent experiments. (C) T cells stained for CD8 and
intracellular IFN-c (D) Percentage total CD8
+ T cells which expressed IFN-c. Values are mean6SD of two different experiments. Total lymphocytes
were gated using FSC/SSC and intracellular IFN-c levels were detected on gated CD4
+ and CD8
+ lymphocytes. Cells were negative for staining with
isotype control antibodies. Exo- exosomes, UI- uninfected. NS-not significant.
doi:10.1371/journal.pone.0002461.g003
stained with anti-CD4-PE, anti-CD8-FITC and anti-CD69-PE-Cy5 (B). Cells were analyzed by flow cytometry. Total lymphocytes were gated using FSC/
SSC and intracellular IFN-c and CD69 levels were detected on gated CD4
+ and CD8
+ lymphocytes. Results are shown as percent positive. Cells were
negative for staining with isotype control antibodies. Results are representative of at least 2 independent experiments.
doi:10.1371/journal.pone.0002461.g002
T Cell Activation by Exosomes
PLoS ONE | www.plosone.org 5 June 2008 | Volume 3 | Issue 6 | e2461DCs pulsed with Toxoplasma antigens was also shown to protect the
mice against subsequent infection [35].
Consistent with these studies, we found that exosomes from M.
bovis BCG infected macrophages can stimulate proliferation and
IFN-c production by pre-sensitized CD4
+ and CD8
+ T cell. The
antigens responsible for this restimulation remain to be defined but
the Ag85 complex is likely one candidate, as at least one member
of this complex is present on exosomes. Members of the Ag85
complex are known to be highly immunogenic [23]. Moreover,
mycobacterial lipids present on exosomes may also function to
stimulate a T cell response through CD1. The restimulation of T
cells by exosomes was significantly enhanced in the presence of
APCs. This suggests that the exosomes function more in cross-
priming then in direct activation of T cells.
Whether an effective vaccine can be generated using exosomes
containing mycobacterial antigens awaits further investigation.
However, previous studies have shown a strong correlation
between expression of IFN-c producing CD4
+ and CD8
+ T cells
and vaccine effectiveness [36]. Moreover, the development of
effector memory cells is also associated with protection [37] [38].
Our results show that intranasal administration of exosomes from
BCG-infected macrophages could activate naı ¨ve T cells and that
these T cells respond with IFN-c production upon restimulation
with BCG antigens ex vivo. These exosomes also induced the
development of effective memory CD4
+ and CD8
+ T cells.
Therefore, our data suggest that exosomes derived from BCG-
infected macrophage could function as an effective vaccine.
Nevertheless, additional experiments are needed to further dissect
the phenotype of the T cells activated upon exosome treatment
and most importantly, determine if intranasal administration of
exosomes isolated from Mtb- or BCG-infected DCs or macro-
phages protects against an Mtb infection.
In summary, the present study indicates that exosomes isolated
from M. bovis BCG infected macrophages can stimulate sensitized
Figure 4. Exosomes from BCG infected macrophages induced effector memory T cells in vivo. Lymphocytes from lungs, MLN and spleens
were isolated from mice intranasally injected with exosomes or PBS and cultured in the presence or absence of BCG lysate. Cells were stained with




low). (B) Percentage of total CD4
+ T cells which were CD44
hi and CD62L
low. Values are mean6SD of two different experiments. (C)
Expression of memory CD8
+ T cells (CD44
hi and CD62L
low). (B) Percentage of total CD8
+ T cells which were CD44
hi and CD62L
low. Values are
mean6SD of two different experiments. Total lymphocytes were gated using FSC/SSC and intracellular IFN-c levels were detected on gated CD4
+ and
CD8
+ lymphocytes. Cells were negative for staining with isotype control antibodies. Exo- exosomes, UI- uninfected. NS-not significant.
doi:10.1371/journal.pone.0002461.g004
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+ and CD8
+ T cells in vitro as well as induce naı ¨ve T cell
activation in vivo. Based on the present study and previous data
indicating that exosomes from mycobacteria-infected macrophag-
es contain TLR ligands and are pro-inflammatory, we hypothesize
that exosomes could promote both innate and acquired immune
responses within the granuloma but distal to the infection foci.
Thus cross-priming by exosomes may help promote the robust
immune response seen in infected individuals. Moreover, we
suggest that exosomes may be a viable candidate for a tuberculosis
vaccine as they have both adjuvant and antigenic qualities.
Figure 5. Activation and maturation of BMDC by exosomes from Mtb- and BCG-infected macrophages. (A) BMDCs following a 12 hr
treatment with exosomes from Mtb, BCG or uninfected (UI) macrophages were labeled with anti-CD11c-FITC and anti-IL-12p40-PE and analyzed by
flow cytometry. (B) BMDCs were cultured in the presence or absence of exosome and 24 hr post-treatment, CD86, MHC II and CD83 expression was
evaluated by flow cytometry. Results are shown as percent positive. The shaded area indicates staining with isotype control antibodies. Results are
representative of at least 2 independent experiments.
doi:10.1371/journal.pone.0002461.g005
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Bacteria culture, complement opsonization and
mycobacterial infections
M. bovis BCG and M. tuberculosis H37RV (Mtb) stocks were
generated as described [13]. Appropriate concentrations of
mycobacteria were suspended in Dulbecco’s modified Eagle’s
medium (DMEM, Gibco) containing 10% normal horse serum as
a source of complement components, followed by a 2 hr
incubation at 37uC. The mouse macrophage cell line J774 was
maintained at 37uCi n5 %C O 2 in DMEM supplemented with
10% fetal bovine serum (FBS) (Life Technologies), 25 mM Na
+-
HEPES, 100-U/ml penicillin and 100-mg/ml streptomycin
(BioWhittaker, Walkersville, MD). Infection of macrophages with
complement-opsonized BCG and Mtb was carried out 3–4 hr
after seeding the cells and infected for 4 hrs as described [39]. An
MOI of 20 was used to reach approximately 80% of the cells
infected.
Mouse infections
Balb/c mice 6–8 weeks of age were used for this study (Harlan,
Indianapolis IN). The mice were housed at the Frieman Life
Science Center, University of Notre Dame and all mouse
experiments were approved by the Institutional Animal Care
and Use Committee. For BCG infection, M. bovis BCG was grown
as described above. At the time of infection, BCG bacilli were
thawed and centrifuged at 1200g for 15 min. The pellet was
washed thrice with sterile PBS, sonicated for 30 sec. and passed
through 27G needle 10 times. Finally, bacilli were suspended in
sterile PBS at the concentration of 2610
7 bacilli/ml. M. bovis BCG
was administered via the retro-orbital intravenous route at a single
dose of 10
6 CFU/mouse in 50 ml of PBS. For some group, BCG
was administered via intranasal route. For intranasal infection,
mice were lightly anesthetized with isoflurane and 30 ml volume
containing 1610
6 bacilli in PBS were administered dropwise to
external nares of the mice (15 ml per nostril) using a micropipette.
As a control group, mice were injected with sterile PBS only. The
infection experiments complied with the Institutional Animal Care
and Use Committee guidelines.
Isolation and Purification of Exosomes
Exosomes were isolated and purified as described previously
[13]. Briefly, for exosome production, cell culture media
containing FCS was centrifuged at 100,000g for 15 hrs to remove
any contaminating exosomes. Culture supernatants were collected
from BCG or uninfected J774 cells after 72 hr and cell debris were
removed by centrifugation at 300g for 10 min at 4uC. Cleared
culture supernatants were filtered through 0.22-mm polyethersul-
fone filters (Corning, NY, USA). Exosomes are 30–90 nm in
diameter and filter freely through 0.22-mm filters. Filtered
supernatants were centrifuged at 10,000g for 30 min, and the
exosomes pelleted from the supernatant at 100,000g for 1 h at
4uC. Exosomes were purified using a sucrose gradient where, the
100,000g pellet was re-suspended in 0.5 ml of 0.25 M sucrose
(20 mM HEPES/NaOH, pH 7.2) and layered on top of a linear
sucrose gradient (0.25–2.0 M sucrose, 20 mM Hepes/NaOH,
pH 7.2). The resulting sample was centrifuged at 100,000g for
15 hr. Gradient fractions (761.5 ml) were collected from the top
of the tube, diluted with 10 ml of PBS and ultracentrifuged at
100,000g for 1 hr. The purified exosomes from BCG-infected,
Mtb-infected or uninfected cells were resuspended in PBS to a
protein concentration of approximately 0.1 to 0.5 mg/ml as
determined by a Micro BCA assay (Pierce, Rockford, IL).
Exosomes were sterilized by filtration through 0.22 mM syringe
sterile filter (Millipore) and stored at 280uC.
Electron microscopy
Exosome pellets were resuspended and fixed in PBS containing
2% glutaraldehyde and then loaded onto Formar/carbon-coated
electron microscopy grids. The samples were contrasted with
uranyl acetate to visualize membrane, and viewed with a Hitachi
H-600 TEM microscope (Hitachi, USA).
Detection of mycobacterial components associated with
exosomes
Mycobacterial components on exosomes were detected by
Western blot. Briefly, 8 mg of exosomes were loaded onto 14%
SDS-PAGE gels, electrophoresed, and transferred onto polyviny-
lidene difluoride membranes (PVDF) (Milipore, Bedford, MA).
The membranes were probed with appropriate dilution of
monoclonal antibodies against Ag85 complex (CS-90), PstS1
(IT-23), a-crystallin (IT-20), HBHA (a-HBHA), LAM (CS-35),
19 kDa lipoprotein (IT-12) and polyclonal antibodies against
whole cell lysate minus LAM (E-293). This was followed by
incubation with HRP-conjugated secondary antibodies, and
detected using an enhanced chemiluminescence kit (Roche
Diagnostic, USA). All antibodies against mycobacterial compo-
nents were obtained from Colorado State University, Colorado,
USA, under TB Vaccine Testing and Research Materials
Contract (NIH-NIAID NO1-A1-40091).
Generation of bone marrow-derived dendritic cells
(BMDCs) and treatment with exosomes
Bone marrow cells were isolated from the tibias and femurs of
Balb/C mice as described previously [39]. Contaminating RBCs
were lysed with ACK lysis buffer (150 mM NH4Cl, 1 mM
KHCO3 and 0.1 EDTA pH 7.3). Cells were cultured in complete
RPMI -1640 containing GM-CSF (200 U/ml). After 12 days in
culture, flow analysis revealed that .85% cells were positive for
CD11c. To evaluate the maturation and activation of BMDCs by
exosome treatment, BMDCs were seeded in 24 well plates at
1610
5 cells/well in 0.5 ml of exosome-free culture media for 3 hr
and then treated with exosomes from BCG, Mtb or uninfected
macrophages (50 mg/ml). After 24 hr cells were washed with
FACS buffer and the expression of MHC II, CD86 and CD83
were determined by flow cytometry using fluorochrome tagged
specific antibodies according to manufacturer instructions. For
intracellular IL-12p40 staining, cells were treated with BCG
exosomes and UI exosomes for 12 hr and adding 2 mM monensin
(Biolegend) in the last 6 hr of infection. Treated cells were first
stained with anti-CD11c-FITC, permeabilized with permeabiliza-
tion buffer (Biolegend), then stained with anti-IL-12p40-PE (BD
Pharmingen, CA), washed with FACS buffer, and analyzed by
flow cytometry.
Treatment of mice with exosomes
Exosomes were administered to mice in three doses at two week
intervals via an intranasal route. At each time points, C57Bl/6
mice were lightly anesthetized with isofluorane and 30 ml volume
containing 25 mg of exosomes from BCG infected and uninfected
macrophages, +/2 30 mg CpG-ODN (Invitrogen) adjuvant in
PBS were administered dropwise to external nares of the mice
(15 ml per nostril) using a micropipette. As a positive control, BCG
was administered as a single dose of 1610
6 CFU/mouse in 30 ml
of PBS via intranasal route as described above. Negative control
groups received only CpG-ODN adjuvant and PBS.
T Cell Activation by Exosomes
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lymph node
Spleens from BCG infected mice were isolated after 30 days of
infection. For isolation of spleen and mediastinal lymph nodes
(MLN) from exosome-treated or untreated animals, mice were
sacrificed two weeks after the final immunization and spleens and
MLNs were aseptically removed. The spleens were then perfused
with RPMI-1640 using 10 ml syringe fitted with 26G needle to
obtain a single cell suspension of splenocytes. MLN cells were
perfused by the pistol of a 3 ml sterile dispovan syringe. The
splenocytes and MLN cell suspension were then centrifuged at
3006g for 10 min. The RBCs were lysed by hypotonic shock using
3 ml ACK lysis buffer for 5 min. The cells were then washed
thrice with RPMI 1640 to remove lysed RBCs and lysis buffer.
Isolation of Lung lymphocytes
Lung lymphocytes from exosome treated and untreated as well
as infected mice were isolated as described previously [40] with
minor modifications. Pooled lungs were homogenized in 6 ml
sterile complete RPMI-1640 in a glass homogenizer and incubated
at 37uC for 2 h with type IV collagenase (125 to 150 U/ml) and
DNase I (50–60 U/ml). Digested lung tissue was then pressed
through a 70-mm nylon mesh and centrifuged at 300g for 10 min.
The cell pellet was then resuspended in complete RPMI-1640
media. The cell suspension was layered on a histoplaque. Density
centrifugation was carried out for 10 min at 3006g at room
temperature. Lung mononuclear cells were obtained from the
interface, washed, counted, and resuspended at 10
6 cells/ml in
complete RPMI-1640 media.
In vitro T cell assays
For Carboxy Fluoroscein Succinimidyl Ester (CFSE) labeling,
splenocytes from infected and control mice were labeled with CFSE
(2.5 mM),and 1610
6 cells/wellwereseededin24-welltissue culture
plates in 500 ml of RPMI-1640 (supplemented with 10% heat
inactivated fetal calf serum, 25 mM HEPES, 2 mM L-glutamine,
1 mM sodium pyruvate, 100 IU/ml penicillin and 100 mg/ml
streptomycin) in the presence or absence of BCG exosomes or UI
exosomes (50 mg/ml). Phytohemagglutinin (PHA) (5 mg/ml) was
used as a positive control for cell viability. The cells were incubated
for 72 hr at 37uC, 5% CO2. Dilution of CFSE after 72 hr was
analyzed by FACS. For CD69 expression, splenocytes were
cultured in the presence or absence of BCG exosomes or uninfected
exosomes (50 mg/ml) for 72 hr as indicated above. Cells were
labeled with anti-CD69-PE-Cy5 (Biolegend), anti-CD4-PE (Biole-
gend)and anti-CD8-PE-Cy5(Biolegend)accordingtomanufacturer
instructions, washed and analyzed by flow cytometry. For
intracellular IFN-c, cells were treated with exosomes for a total of
12 hrs with the final 6 hours in presence of 2 mM monensin. These
cells were first stained with anti-CD4-PE and anti-CD8-PE-Cy5
then permeabilized with permeabilization buffer (Biolegend), and
stained with anti-IFN-c-FITC (Biolegend BD pharmingen, San
Diago CA) according to manufacturer instructions, washed with
FACSbufferandanalyzedbyflowcytometry.ForintracellularIFN-
c staining of lymphocytes from lung, spleen, and MLN of exosomes
treated and untreated mice were incubated with BCG lysate
(10 mg/ml) for a total of 12 hrs with the final 6 hours in presence of
2 mM monensin. These cells were first stained with anti-CD4-PE
and anti-CD8-PE then permeabilized with permeabilization buffer
(Biolegend), and stained with anti-IFN-c-FITC (Biolegend) accord-
ing to manufacturer instructions, washed with FACS buffer and
analyzed by flow cytometry.
T cells were purified from splenocytes of BCG infected animals
by T cell specific negative selection on magnetic cell sorting
(MACS) columns (Miltenyi Biotech) using Pan T cell isolation kit
(Miltenyi Biotech) according to manufacturer instructions. T cells
(5610
5) were cultured together with autologous BMDCs (1610
5)
in the presence or absence of BCG exosomes or uninfected
exosomes (50 mg/ml). Intracellular IFN-c and CD69 expression
were analyzed 12 and 72 hr post-exosome treatment respectively
as described above.






Tri-color flow cytometry was done for analysis of memory
phenotype. Two weeks after the final immunization or 30 days
after BCG infection, lungs, MLNs and spleen cells were isolated
from exosomes treated and untreated animals. Cells were washed
with FACS wash buffer and incubated on ice with panel of
antibodies: antiCD4-PE, antiCD8-PE, antiCD44-PECy5, an-
tiCD62L-FITC at the concentration of 0.5 mg/million cells in
50 ml of FACS buffer for 30 min at 4uC. Cells were then washed
and fixed with 2% paraformaldehyde and analyzed by flow
cytometry. All the analysis was done with an acquisition of
100,000 events. Gating of CD4
+ and CD8
+ cells in the
lymphocyte-rich regions was based on forward-angle light scatter
and log Phycoerythrin fluorescence (FL2-H) and then the
expression of CD62L (FL1-H) and CD44 (FL4-H) on CD4
+ or
CD8
+ gated lymphocytes were analyzed. Isotype controls for cells
stained with antibodies were analyzed at each time point.
Statistical Analysis
Wherever applicable, data were analyzed using the Microsoft
Excel Software program. Group comparisons were performed by
using the unpaired Student’s t test.
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